Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 2.16 NOK
Change Today -0.02 / -0.92%
Volume 355.8K
As of 10:25 AM 07/7/15 All times are local (Market data is delayed by at least 15 minutes).

bionor pharma asa (BIONOR) Snapshot

2.17 NOK
Previous Close
2.18 NOK
Day High
2.21 NOK
Day Low
2.16 NOK
52 Week High
05/4/15 - 3.33 NOK
52 Week Low
03/18/15 - 2.02 NOK
Market Cap
Average Volume 10 Days
-0.28 NOK
Shares Outstanding
Dividend Yield
Current Stock Chart for BIONOR PHARMA ASA (BIONOR)

Related News

No related news articles were found.

bionor pharma asa (BIONOR) Related Businessweek News

No Related Businessweek News Found

bionor pharma asa (BIONOR) Details

Bionor Pharma ASA, a biotechnology company, is engaged in developing peptide based vaccines against viral diseases, primarily human immunodeficiency virus (HIV). The company’s HIV vaccine candidates in clinical development include Vacc-4x for reducing viral load and killing virus producing cells; and Vacc-C5 is indicated for the formation of antibodies against HIV in humans. The company is also developing Vacc-HIV, a preclinical phase vaccine, using the combination of Vacc-4x and Vacc-C5 vaccines; and Vacc-Flu, a preclinical phase influenza vaccine. In addition, it is developing vaccines for other viral diseases, including Hepatitis C, cytomegalovirus infection, and human papillomavirus infection. Further, the company provides nutraceutical products, such as Nutri5 and NutriPro. It operates in Norway and Europe, including Russia. The company was formerly known as Nutri Pharma ASA and changed its name to Bionor Pharma ASA in June 2010. Bionor Pharma ASA was founded in 1993 and is based in Oslo, Norway.

10 Employees
Last Reported Date: 04/13/15
Founded in 1993

bionor pharma asa (BIONOR) Top Compensated Officers

Head of Development and Executive Vice Presid...
Total Annual Compensation: 1.9M NOK
Compensation as of Fiscal Year 2013.

bionor pharma asa (BIONOR) Key Developments

Bionor Pharma ASA Announces Board Changes

Bionor Pharma ASA at its AGM held on May 13, 2015, approved the appointment of Russell G. Greig as Chairman of the Board of the directors for the period of two years. Thomas Hofstaetter, Bernd R. Seizinger and Kirsten Aarup Drejer was elected as new Board members for a period of two years. The Board members Jerry B. Zeldis and Benedicte Fossum were not up for election in 2015.

Bionor Pharma ASA Proposes to Approve Articles of Association

Bionor Pharma ASA announced that at its AGM held on May 13, 2015, the shareholders approved the amendments to its articles of association.

Bionor Pharma ASA Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Bionor Pharma ASA reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenues of NOK 4,200,000 in last year. Operating loss was NOK 20,456,000 against NOK 22,069,000 a year ago. Loss before tax was NOK 20,211,000 compared with NOK 21,642,000 a year ago. Net loss was NOK 20,211,000 against NOK 21,642,000 a year ago. Loss per share was NOK 0.08 compared with NOK 0.10 a year ago. EBITDA was NOK 17,663,000. Net cash from operating activities was NOK 17,827,000 against NOK 18,399,000 a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIONOR:NO 2.16 NOK -0.02

BIONOR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BIONOR.
View Industry Companies

Industry Analysis


Industry Average

Valuation BIONOR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 792.2x
Price/Book 3.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 672.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIONOR PHARMA ASA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at